{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:42Z","timestamp":1787017062981,"version":"build-2736575974"},"reference-count":22,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["NIH\/NIDCR R01DE026801"],"award-info":[{"award-number":["NIH\/NIDCR R01DE026801"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI","award":["R21 CA252441"],"award-info":[{"award-number":["R21 CA252441"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,7,10]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Mucosal melanomas constitute a subtype of melanoma with less effective treatments than cutaneous melanomas. We present a case of oral mucosal melanoma that recurred despite multiple resections and adjuvant temozolomide. Treatment with topical imiquimod combined with pembrolizumab achieved remission. A 56-year-old woman presented with a pigmented mass on her left anterior hard palate. Biopsy revealed malignant melanoma. The patient had resection with neck dissection with 3 months of adjuvant temozolomide due to positive margins. Malignant melanoma involving the hard palate recurred 1\u2009year later requiring additional resection. Two years later, two additional pigmented lesions were found; further resections were deferred due to expected morbidity. Following 6 weeks of topical imiquimod treatment, the lesions shrunk significantly. Adjuvant pembrolizumab was added and complete histopathologic remission was observed in 6 months. The patient remained in remission for 4 years before new melanoma in situ was diagnosed, requiring five additional months of imiquimod. As of April 2021, there is no clinical evidence of melanoma. There are limited reports of oral melanoma treated with topical imiquimod. Here, imiquimod administered in combination with pembrolizumab achieved complete pathologic response.<\/jats:p>","DOI":"10.1136\/jitc-2020-001219","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T12:00:21Z","timestamp":1635508821000},"page":"e001219","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-4058","authenticated-orcid":false,"given":"Tejus","family":"Satish","sequence":"first","affiliation":[{"name":"Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Levin","sequence":"additional","affiliation":[{"name":"Cell IDx, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Pathology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"2025100309513208000_9.10.e001219.1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G"},{"key":"2025100309513208000_9.10.e001219.2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0034"},{"key":"2025100309513208000_9.10.e001219.3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(87)90289-3"},{"key":"2025100309513208000_9.10.e001219.4","doi-asserted-by":"crossref","first-page":"MMT11","DOI":"10.2217\/mmt-2018-0003","article-title":"Combatting mucosal melanoma: recent advances and future perspectives","volume":"5","author":"Tyrrell","year":"2018","journal-title":"Melanoma Manag"},{"key":"2025100309513208000_9.10.e001219.5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/DSS.0000000000001115","article-title":"Long-term outcomes of melanoma in situ treated with topical 5% imiquimod cream: a retrospective review","volume":"43","author":"Park","year":"2017","journal-title":"Dermatol Surg"},{"key":"2025100309513208000_9.10.e001219.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20866"},{"key":"2025100309513208000_9.10.e001219.7","doi-asserted-by":"publisher","DOI":"10.1002\/jso.10247"},{"key":"2025100309513208000_9.10.e001219.8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20775"},{"key":"2025100309513208000_9.10.e001219.9","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.129.8.864"},{"key":"2025100309513208000_9.10.e001219.10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24976"},{"key":"2025100309513208000_9.10.e001219.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2025100309513208000_9.10.e001219.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30259"},{"key":"2025100309513208000_9.10.e001219.13","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4804"},{"key":"2025100309513208000_9.10.e001219.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01151.x"},{"key":"2025100309513208000_9.10.e001219.15","article-title":"Imiquimod 5 percent cream and the treatment of cutaneous malignancy","volume":"10","author":"Navi","year":"2004","journal-title":"Dermatol Online J"},{"key":"2025100309513208000_9.10.e001219.16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157 Suppl 2","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"key":"2025100309513208000_9.10.e001219.17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","article-title":"Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type","volume":"72","author":"Swetter","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025100309513208000_9.10.e001219.18","first-page":"443","article-title":"Melanoma in situ treated with topical imiquimod for management of persistently positive margins: a review of treatment methods","volume":"15","author":"Fan","year":"2015","journal-title":"Ochsner J"},{"key":"2025100309513208000_9.10.e001219.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.8829"},{"key":"2025100309513208000_9.10.e001219.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70979-2"},{"key":"2025100309513208000_9.10.e001219.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7"},{"key":"2025100309513208000_9.10.e001219.22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00680"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:51:37Z","timestamp":1759510297000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,29]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/jitc-2020-001219"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001219","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}